FDA May Disclose Clinical Investigator Financial Data In Product Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Final guidance on drug sponsors’ responsibilities for financial disclosures related to clinical investigators who participate revises definitions of due diligence and covered clinical studies from the draft published in 2011, but retains FDA’s statement that it may include such disclosures in the documents released upon product approval for marketing.
You may also be interested in...
Regulatory News In Brief
FDA released a final rule on protections for children in clinical trials and a final guidance on financial disclosures by investigators. More regulatory news.
Clinical Investigators' Financial Disclosures Might Become Public – Guidance
FDA is signaling greater readiness to publicly disclose what was once considered proprietary information on the financial ties of clinical trial investigators.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.